Cargando…

Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma

BACKGROUND AND OBJECTIVES: Surgical treatment is still the mainstay of curative therapy for retroperitoneal liposarcoma (RLPS), but often recurs after surgical resection. We aimed to establish a nomogram for postoperative recurrence of RLPS based on the Asian population. METHODS: Patients after surg...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Aobo, Wu, Qian, Tong, Hanxing, Zhang, Yong, Lu, Weiqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402954/
https://www.ncbi.nlm.nih.gov/pubmed/34466033
http://dx.doi.org/10.2147/CMAR.S321324
_version_ 1783745913041190912
author Zhuang, Aobo
Wu, Qian
Tong, Hanxing
Zhang, Yong
Lu, Weiqi
author_facet Zhuang, Aobo
Wu, Qian
Tong, Hanxing
Zhang, Yong
Lu, Weiqi
author_sort Zhuang, Aobo
collection PubMed
description BACKGROUND AND OBJECTIVES: Surgical treatment is still the mainstay of curative therapy for retroperitoneal liposarcoma (RLPS), but often recurs after surgical resection. We aimed to establish a nomogram for postoperative recurrence of RLPS based on the Asian population. METHODS: Patients after surgical resection at the South Hospital of Zhongshan Hospital/Shanghai Public Health Clinical Center between August 2011 and December 2020 were included. The enrolled patients are randomly divided into training set and test set according to the ratio of 7:3. Prognostic factors were chosen based on Akaike Information Criterion, and the nomogram was built based on Cox regression and then internally validated through calibration plots and concordance index (C-index). RESULTS: A total of 447 patients were included. Gender, age, presentation status, organ invasion and FNCLCC grade were used to build nomogram. The calibration plots showed that RFS predicted probabilities are identical to the actual RFS rates. The C-index of the nomogram was 0.703 (95% CI 0.623–0.783) in the training set and 0.695 (95% CI 0.565–0.825) in test set. CONCLUSION: The nomogram we established can accurately predict postoperative recurrence of RLPS patients for Asian population.
format Online
Article
Text
id pubmed-8402954
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84029542021-08-30 Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma Zhuang, Aobo Wu, Qian Tong, Hanxing Zhang, Yong Lu, Weiqi Cancer Manag Res Original Research BACKGROUND AND OBJECTIVES: Surgical treatment is still the mainstay of curative therapy for retroperitoneal liposarcoma (RLPS), but often recurs after surgical resection. We aimed to establish a nomogram for postoperative recurrence of RLPS based on the Asian population. METHODS: Patients after surgical resection at the South Hospital of Zhongshan Hospital/Shanghai Public Health Clinical Center between August 2011 and December 2020 were included. The enrolled patients are randomly divided into training set and test set according to the ratio of 7:3. Prognostic factors were chosen based on Akaike Information Criterion, and the nomogram was built based on Cox regression and then internally validated through calibration plots and concordance index (C-index). RESULTS: A total of 447 patients were included. Gender, age, presentation status, organ invasion and FNCLCC grade were used to build nomogram. The calibration plots showed that RFS predicted probabilities are identical to the actual RFS rates. The C-index of the nomogram was 0.703 (95% CI 0.623–0.783) in the training set and 0.695 (95% CI 0.565–0.825) in test set. CONCLUSION: The nomogram we established can accurately predict postoperative recurrence of RLPS patients for Asian population. Dove 2021-08-24 /pmc/articles/PMC8402954/ /pubmed/34466033 http://dx.doi.org/10.2147/CMAR.S321324 Text en © 2021 Zhuang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhuang, Aobo
Wu, Qian
Tong, Hanxing
Zhang, Yong
Lu, Weiqi
Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma
title Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma
title_full Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma
title_fullStr Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma
title_full_unstemmed Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma
title_short Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma
title_sort development and validation of a nomogram for predicting recurrence-free survival of surgical resected retroperitoneal liposarcoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402954/
https://www.ncbi.nlm.nih.gov/pubmed/34466033
http://dx.doi.org/10.2147/CMAR.S321324
work_keys_str_mv AT zhuangaobo developmentandvalidationofanomogramforpredictingrecurrencefreesurvivalofsurgicalresectedretroperitonealliposarcoma
AT wuqian developmentandvalidationofanomogramforpredictingrecurrencefreesurvivalofsurgicalresectedretroperitonealliposarcoma
AT tonghanxing developmentandvalidationofanomogramforpredictingrecurrencefreesurvivalofsurgicalresectedretroperitonealliposarcoma
AT zhangyong developmentandvalidationofanomogramforpredictingrecurrencefreesurvivalofsurgicalresectedretroperitonealliposarcoma
AT luweiqi developmentandvalidationofanomogramforpredictingrecurrencefreesurvivalofsurgicalresectedretroperitonealliposarcoma